Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). Moderna to pay $950M noncontingent lump sum to Arbutus/Genevant on or before July 8, 2026, resolving all LNP patent litigation.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Moderna to pay $950M noncontingent lump sum to Arbutus/Genevant on or before July 8, 2026, resolving all LNP patent litigation
- Additional $1.3B contingent payment triggered if Federal Circuit affirms rejection of Moderna's §1498 defense; prorated if only partial win; repayable with interest if victory later overturned
- Arbutus entitled to 20% of net proceeds after litigation costs under its Genevant license agreement: implies ~$190M from guaranteed payment alone
- Moderna receives fully paid-up, royalty-free, irrevocable non-exclusive license for Spikevax, mNEXSPIKE, mRESVIA, and other SM-102 LNP-based infectious disease mRNA vaccines
- Contingent $1.3B upside remains binary on appellate outcome: Federal Circuit ruling on §1498 government contractor defense is key near-term catalyst for ABUS
Item 8.01 · Other Events
- Arbutus and partner Genevant entered a Settlement Agreement, announced March 3, 2026: nature, terms, and financial impact disclosed only via Exhibit 99.1
- Settlement agreements typically resolve patent/licensing disputes; material to ABUS given its LNP (lipid nanoparticle) IP monetization strategy
- Investors should review Exhibit 99.1 press release for deal specifics, including any cash proceeds or royalty arrangements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.